Tanoira Cassagne Abogados advised SAVANT PHARM S.A. on the issuance of Public Notes
Tanoira Cassagne Abogados advised SAVANT PHARM S.A. (the “Company“), in the issuance in the local market of the Series VII Class “N” Notes for a total aggregate amount of $150,000,000. and Series VII Class “O” Notes for a total aggregate amount of $261,517,726. (at the Initial Exchange Rate) (the “Notes“) under their Global Notes Program for an amount up to $1,200,000,000 (or its Equivalent in other currencies or units of measurement, monetary or value)
The placement of the Notes took place on May 6, 2021 with Trust Capital S.A. as Arranger and Placement Agent, together with AR Partners S.A. and Comafi Bank as Placement Agents for the Notes. The Notes were issued on May 10, 2021.
The Class “N” Notes, $150,000,000.- (Pesos one hundred and fifty million) are due on November 10, 2022, with a variable interest rate consisting of the Badlar Rate plus a cut-off margin of 6,5%, as a result of the bidding process. Interest payable on a quarterly basis.
The Class “O” Notes, UVA 3,487,368 (equivalent to $261,517,726), are due on November 10, 2023, with a fixed nominal annual interest rate of 5% as result of the bidding process. Interest payable on a quarterly basis.
The Company’s principal activity is the manufacture and marketing of drugstore, pharmaceutical and medicinal products.
The Company’s Notes have been authorized for listing and negotiating on the Bolsas y Mercados Argentinos S.A. (BYMA) and Mercado Abierto Electrónico S.A. (MAE) respectively.
Legal counsel on the transaction.
Tanoira Cassagne Abogados: Through its team led by its Partners Alexia Rosenthal and Jaime Uranga, and Associates Juan Sanguinetti and Pilar Domínguez Pose.